EW250117P60000
- 0.05
- -0.10-66.67%
Edwards Lifesciences Newsroom
Bernstein Upgrades Edwards Lifesciences(EW.US) to Hold Rating, Raises Target Price to $74
RBC Capital Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $85
RBC Capital Reaffirms Their Buy Rating on Edwards Lifesciences (EW)
Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Is Edwards Lifesciences (NYSE:EW) A Risky Investment?
Today's Analyst Rating | ServiceNow Price Target Raised to $1210 by RBC Capital, Goldman Sachs Price Target Raised to $623 by Evercore
Jan 3, Wall Street analysts have updated their stock ratings today including $ServiceNow(NOW.US)$ and $Goldman Sachs(GS.US)$.
Evercore Maintains Edwards Lifesciences(EW.US) With Hold Rating, Raises Target Price to $75
Edwards Lifesciences Corporation (EW): Among the Cheap Healthcare Stocks to Buy Heading Into 2025
A Look At The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Edwards Lifesciences Scores a Win at CMS for TTVR
Edwards Lifesciences Corporation (NYSE:EW) Is Largely Controlled by Institutional Shareholders Who Own 85% of the Company
Jim Cramer: Is Edwards Lifesciences (EW) Poised for a Comeback?
Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards
Daily short sale tracking: Micron Technology's short volume increased by 4 million, with a short sale ratio of 11%
Micron Technology(MU.US) ranked top of the list had the largest change in short volume (4.13 million shares), and the short volume ratio of Targa Resources(TRGP.US) reached 45.12%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Is the Options Market Predicting a Spike in Edwards (EW) Stock?
Deutsche Bank Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $85
Deutsche Bank Sticks to Its Buy Rating for Edwards Lifesciences (EW)
Baird Adjusts Edwards Lifesciences Price Target to $70 From $68, Maintains Neutral Rating
Morgan Stanley Downgrades Edwards Lifesciences(EW.US) to Sell Rating, Cuts Target Price to $46